Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase 2 Completed
105 enrolled 8 charts
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia
Phase 3 Completed
6,136 enrolled
LAL1308
Phase NA Completed
76 enrolled
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 2 Completed
25 enrolled
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Phase 2 Completed
134 enrolled
AIEOP LLA 2000
Phase 3 Completed
2,039 enrolled
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Phase 2 Completed
120 enrolled
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
Phase 2 Unknown
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Phase 3 Completed
120 enrolled
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 2 Unknown
Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer
Phase 2 Completed
111 enrolled
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Phase 2 Completed
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase 3 Completed
4,559 enrolled
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
Phase 2 Completed
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase 3 Unknown
4,000 enrolled
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
Phase 1 Unknown